1.590USD+3.92%Mkt Cap: 2.59M $P/E: —2d ago
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humaniz…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT) New data presented at EACR 2026 highlighted anti-tumor activity, improved safety characteristics, and pharmacokinetic advantages for Purple Biotech’s lead immunotherapy candidate as it advances toward human testing. Key Investor TakeawaysPurple Biotech (NASDAQ:PPBT) reported new preclinical IM1240 data supporting advancement into a planned first-in-human study in 2027. | ||